Tag: AACR

Synergy Pharmaceuticals to Present at AACR Synergy&#39s second GC-C agonist SP-333 is at present in pre-clinical development to treat inflammatory bowel diseases. Much more details is accessible at https://www.synergypharma.com . Fox Chase Cancer Center is 1 of the top cancer study and … Read far more on MarketWatch (press release) Canadian College of Naturopathic Medicine…